In silico analyses of the KIRC data indicated epigenetic silencing of TACSTD2 in RCC and confirmed an association of methylation of TACSTD2 with clinically aggressive subsets of ccRCC. This evidence concerns the gene TACSTD2 and nonpapillary renal cell carcinoma.